Clinical trial
A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer
NCT00238420 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 26, 2005
- Completion date
- May 20, 2022
- Enrollment
- 70 (actual)
- Sites
- 184
Conditions
As the registry lists them; a condition with its own page is linked.
bladder urothelial carcinoma, stage i bladder cancer ajcc v6 and v7, stage ii bladder cancer ajcc v6 and v7, stage iii bladder cancer ajcc v6 and v7